ABSTRACT
Vitamin D receptor (VDR) ligands are therapeutic agents for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism. VDR ligands also show immense potential as therapeutic agents for autoimmune diseases and cancers of skin, prostate, colon, and breast as well as leukemia. However, the major side effect of VDR ligands that limits their expanded use and clinical development is hypercalcemia that develops as a result of the action of these compounds mainly on intestine. In order to discover VDR ligands with less hypercalcemia liability, we sought to identify tissue-selective VDR modulators (VDRMs) that act as agonists in some cell types and lack activity in others. Here, we describe LY2108491 and LY2109866 as nonsecosteroidal VDRMs that function as potent agonists in keratinocytes, osteoblasts, and peripheral blood mononuclear cells but show poor activity in intestinal cells. Finally, these nonsecosteroidal VDRMs were less calcemic in vivo, and LY2108491 exhibited more than 270-fold improved therapeutic index over the naturally occurring VDR ligand 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] in an in vivo preclinical surrogate model of psoriasis.
Subject(s)
Acetates/pharmacology , Arylsulfonates/pharmacology , Receptors, Calcitriol/metabolism , Thiophenes/pharmacology , Vitamin D/analogs & derivatives , Vitamin D/pharmacology , Acetates/chemical synthesis , Acetates/metabolism , Animals , Arylsulfonates/chemical synthesis , Arylsulfonates/metabolism , Caco-2 Cells , Calcitriol/metabolism , Calcitriol/pharmacology , Cell Proliferation , Cells, Cultured , Colonic Neoplasms/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Female , Humans , Hypercalcemia/metabolism , Intestines , Keratinocytes/drug effects , Keratinocytes/metabolism , Ligands , Mice , Mice, Hairless , Mice, Inbred C57BL , Mice, Inbred Strains , Models, Biological , Osteoblasts/drug effects , Osteoblasts/metabolism , Psoriasis/drug therapy , Rats , Receptors, Calcitriol/agonists , Signal Transduction , Species Specificity , Thiophenes/chemical synthesis , Thiophenes/metabolism , Transcription, Genetic , Tumor Cells, Cultured , Vitamin D/chemical synthesis , Vitamin D/metabolismABSTRACT
We have recently shown that in colon cancer cells, Vitamin D receptor (VDR) interacts with the catalytic subunit of Ser/Thr protein phosphatases, PP1c and PP2Ac, and induces their enzymatic activity in a ligand-dependent manner. The VDR-PP1c and VDR-PP2Ac interactions were ligand independent in vivo, and 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3))-mediated increase in VDR-associated phosphatase activity resulted in dephosphorylation and inactivation of p70S6 kinase in colon cancer cells. Here, we demonstrate that in myeloid leukemia cells, 1,25(OH)(2)D(3) treatment increased the Thr389 phosphorylation of p70S6 kinase. Accordingly, 1,25(OH)(2)D(3) decreased VDR-associated Ser/Thr protein phosphatase activity by dissociating VDR-PP1c and VDR-PP2Ac interactions. Further, 1,25(OH)(2)D(3) increased the association between VDR and Thr389 phosphorylated p70S6 kinase. Finally, by using non-secosteroidal VDR ligands, we demonstrate a separation between transactivation and p70S6 kinase phosphorylation activities of VDR and show pharmacologically that p70S6 kinase phosphorylation correlates with HL-60 cell differentiation.
Subject(s)
Phosphoprotein Phosphatases/metabolism , Receptors, Calcitriol/metabolism , Ribosomal Protein S6 Kinases/metabolism , Cell Line, Tumor , Cell Separation , Flow Cytometry , Humans , Ligands , Phosphorylation , Protein Binding , Protein Phosphatase 1ABSTRACT
The vitamin D receptor (VDR) belongs to the thyroid hormone/retinoid receptor subfamily of nuclear receptors and functions as a heterodimer with retinoid X receptor (RXR). The RXR-VDR heterodimer, in contrast to other members of the class II nuclear receptor subfamily, is nonpermissive where RXR does not bind its cognate ligand, and therefore its role in VDR-mediated transactivation by liganded RXR-VDR has not been fully characterized. Here, we show a unique facet of the intermolecular RXR-VDR interaction, in which RXR actively participates in vitamin D3-dependent gene transcription. Using helix 3 and helix 12 mutants of VDR and RXR, we provide functional evidence that liganded VDR allosterically modifies RXR from an apo (unliganded)- to a holo (liganded)-receptor conformation, in the absence of RXR ligand. As a result of the proposed allosteric modification of RXR by liganded VDR, the heterodimerized RXR shows the "phantom ligand effect" and thus acquires the capability to recruit coactivators steroid receptor coactivator 1, transcriptional intermediary factor 2, and amplified in breast cancer-1. Finally, using a biochemical approach with purified proteins, we show that RXR augments the 1,25-dihydroxyvitamin D3-dependent recruitment of transcriptional intermediary factor 2 in the context of RXR-VDR heterodimer. These results confirm and extend the previous observations suggesting that RXR is a significant contributor to VDR-mediated gene expression and provide a mechanism by which RXR acts as a major contributor to vitamin D3-dependent transcription.
Subject(s)
Receptors, Calcitriol/metabolism , Receptors, Retinoic Acid/metabolism , Transcription Factors/metabolism , Transcriptional Activation , Vitamin D/analogs & derivatives , Allosteric Regulation , Dimerization , HeLa Cells , Histone Acetyltransferases , Humans , Mutation/genetics , Nuclear Receptor Coactivator 1 , Nuclear Receptor Coactivator 2 , Nuclear Receptor Coactivator 3 , Protein Structure, Tertiary , Receptors, Calcitriol/chemistry , Receptors, Calcitriol/genetics , Receptors, Retinoic Acid/chemistry , Receptors, Retinoic Acid/genetics , Retinoid X Receptors , Transcription Factors/chemistry , Transcription Factors/genetics , Transcriptional Activation/drug effects , Vitamin D/pharmacologyABSTRACT
We provide evidence of a cross-talk between nuclear receptor and Ser/Thr protein phosphatases and show that vitamin D receptor (VDR) interacts with the catalytic subunit of protein phosphatases, PP1c and PP2Ac, and induces their enzymatic activity in a ligand-dependent manner. PP1c specifically interacts with VDR but not retinoic acid receptor alpha and retinoid X receptor alpha in yeast. Although VDR-PP1c and VDR-PP2Ac interaction is ligand-independent in vivo, 1alpha,25-dihydroxy-vitamin D(3) induces VDR-associated phosphatase activity. Further, VDR modulation of PP1c/PP2Ac activity results in a rapid and specific dephosphorylation and inactivation of their substrate, p70 S6 kinase (p70(S6k)). Finally, we demonstrate that the endogenous VDR, PP1c or PP2Ac, and p70(S6k) are present in a ternary complex in vivo, and the interaction of p70(S6k) with the VDR-PP complex is modulated by the phosphorylation state of the kinase. Since p70(S6k) is essential for G(1)-S transition, our results provide a molecular basis of 1alpha,25-dihydroxyvitamin D(3)-induced G(1) block in colon cancer cells.
